BioVentrix introduces minimally invasive myocardial anchoring system

25 October 2012 (Last Updated October 25th, 2012 18:30)

BioVentrix has launched a myocardial anchoring system for patients with ischemic cardiomyopathy.

BioVentrix has launched a myocardial anchoring system for patients with ischemic cardiomyopathy.

The new technology, Revivent, is designed for use in less invasive ventricular enhancement (LIVE) procedures to improve the function of the left ventricle (LV) without an incision in the heart wall, and to reduce LV volume by excluding scarred myocardial tissue from the chamber.

Drexel University College of Medicine cardiothoracic surgery professor Dr Andrew Wechsler said fluoroscopic control allows precise placement of the anchors that exclude the scarred segment of the ventricles and complete the restoration process.

"Intraoperative monitoring documents the excellent hemodynamics present at the end of the procedure without vasoactive support," Wechsler said.

In addition, the use of the technology in LIVE procedures reduces the harmful effects of high-tensile forces and increased pumping efficiency in the ventricle, and restores it into conical geometry, resulting in enhanced performance of the remaining myocardium.

"Fluoroscopic control allows precise placement of the anchors that exclude the scarred segment of the ventricles and complete the restoration process."

BioVentrix president and CEO Ken Miller said the company's Revivent system will help cardiac surgery teams ensure optimal clinical outcomes and improve the quality of life for heart failure patients with very minimal risk in comparison to currently available conventional LV reconstruction surgical procedures.

"Scientific literature suggests that existing treatment options such as medication or pacemaker therapy, are not effective in over half of those treated, which exemplifies the need for minimally invasive cardiac surgery to treat the growing population of patients who suffer from heart failure," Miller said.

The company has also initiated a 50-patient Phase II study to broaden the clinical experience base of Revivent system amongst heart failure institutions and expand awareness of the LIVE technique.